Drug Trial Radar · NCT07761013
Yanlishuang Buccal Dropping Pills for Acute Pharyngitis
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Mar 26, 2027
Study completion Jun 29, 2027
Sponsor
- Lead sponsor
- Beijing University of Chinese MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute pharyngitis commonly causes sore throat and pain on swallowing. This multicenter trial will compare Yanlishuang Buccal Dropping Pills with a matching placebo in 400 adults aged 18 to 65 years whose acute pharyngitis began within 48 hours and whose baseline throat-pain visual analog scale score is at least 4. Participants will be randomized 1:1 and treated under double-blind conditions. Each group will use four buccal dropping pills 4 to 6 times daily at intervals of at least 2 hours for up to 5 days. Participants whose sore throat resolves after at least 72 hours and remains absent for at least 24 hours may stop treatment early. The primary outcome is time to complete sore throat resolution. Secondary outcomes assess immediate pain relief, onset and resolution of pain, symptom and physical-sign response, complications, and work absence. Safety will be assessed using physical examinations, vital signs, laboratory tests, electrocardiograms, and adverse events.
Conditions
- Acute Pharyngitis
Interventions
Yanlishuang Buccal Dropping PillsDrug
Miao medicine buccal dropping pills supplied by the sponsor. The protocol lists Aipian/natural borneol, Blumea balsamifera oil, peppermint oil, menthol, and monoammonium glycyrrhizinate, with polyethylene glycol 6000 as excipient. Dose: 4 pills buccally per administration, 4 to 6 administrations per day, at intervals of at least 2 hours, for up to 5 days.
Yanlishuang Buccal Dropping Pills PlaceboDrug
Matching placebo with identical dosage form, weight, packaging, schedule, and administration: 4 pills buccally per administration, 4 to 6 administrations per day, at intervals of at least 2 hours, for up to 5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to complete sore throat resolutionTime frame: From the first dose until complete sore throat resolution, assessed up to Day 6.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Harbin, Heilongjiang, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China
Jiangxi Provincial Hospital of Traditional Chinese Medicine
Nanchang, Jiangxi, China
First Affiliated Hospital of Shandong University of Traditional Chinese Medicine / Shandong Provincial Hospital of Traditional Chinese Medicine
Jinan, Shandong, China
Shanghai Municipal Hospital of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine / Sichuan Provincial Hospital of Traditional Chinese Medicine
Chengdu, Sichuan, China
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Yunnan University of Chinese Medicine / Yunnan Provincial Hospital of Traditional Chinese Medicine
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.